The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
MeSH Review

Leprosy, Lepromatous

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Leprosy, Lepromatous

 

Psychiatry related information on Leprosy, Lepromatous

 

High impact information on Leprosy, Lepromatous

 

Chemical compound and disease context of Leprosy, Lepromatous

 

Biological context of Leprosy, Lepromatous

 

Anatomical context of Leprosy, Lepromatous

 

Gene context of Leprosy, Lepromatous

  • The impaired function of this TLR2 variant provides a molecular mechanism for the poor cellular immune response associated with lepromatous leprosy and may have important implications for understanding the pathogenesis of other mycobacterial infections [27].
  • The CD40-CD40L interaction, which is not evident in lepromatous leprosy, probably participates in the cell-mediated immune response to microbial pathogens [28].
  • Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions [29].
  • However, the association between mutations of the IL12RB1, IL12RB2, and IFNGR1 encoding genes and lepromatous leprosy has not been studied [21].
  • Our main goal was to determine whether deficiency in interferon-gamma (IFN-gamma) production shown by peripheral blood mononuclear cells (PBMC) from lepromatous leprosy (LL) patients, could be overcome by reconstituting in vitro the appropriate signals (by means of addition of anti-CD28 and anti-CD80 monoclonal antibodies) [30].
 

Analytical, diagnostic and therapeutic context of Leprosy, Lepromatous

References

  1. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. Nathan, C.F., Kaplan, G., Levis, W.R., Nusrat, A., Witmer, M.D., Sherwin, S.A., Job, C.K., Horowitz, C.R., Steinman, R.M., Cohn, Z.A. N. Engl. J. Med. (1986) [Pubmed]
  2. Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. Arnoldi, J., Gerdes, J., Flad, H.D. Am. J. Pathol. (1990) [Pubmed]
  3. In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. Modlin, R.L., Hofman, F.M., Horwitz, D.A., Husmann, L.A., Gillis, S., Taylor, C.R., Rea, T.H. J. Immunol. (1984) [Pubmed]
  4. Polymorphonuclear cell function in the various polar types of leprosy and erythema nodosum leprosum. Sher, R., Anderson, R., Glover, A., Wadee, A.A. Infect. Immun. (1978) [Pubmed]
  5. Interleukin-1 released by blood-monocyte-derived macrophages from patients with leprosy. Ridel, P.R., Jamet, P., Robin, Y., Bach, M.A. Infect. Immun. (1986) [Pubmed]
  6. Undernutrition in lepromatous leprosy, Part II. Altered levels of serum elements. Their association with the disease and not with food deprivation. Rao, K.N., Saha, K. Leprosy review. (1986) [Pubmed]
  7. T-cell release of granulysin contributes to host defense in leprosy. Ochoa, M.T., Stenger, S., Sieling, P.A., Thoma-Uszynski, S., Sabet, S., Cho, S., Krensky, A.M., Rollinghoff, M., Nunes Sarno, E., Burdick, A.E., Rea, T.H., Modlin, R.L. Nat. Med. (2001) [Pubmed]
  8. The systemic influence of recombinant interleukin 2 on the manifestations of lepromatous leprosy. Kaplan, G., Britton, W.J., Hancock, G.E., Theuvenet, W.J., Smith, K.A., Job, C.K., Roche, P.W., Molloy, A., Burkhardt, R., Barker, J. J. Exp. Med. (1991) [Pubmed]
  9. Immunoreactivity of a 70 kD protein purified from Mycobacterium bovis Bacillus Calmette-Guerin by monoclonal antibody affinity chromatography. Britton, W.J., Hellqvist, L., Basten, A., Inglis, A.S. J. Exp. Med. (1986) [Pubmed]
  10. An analysis of in vitro T cell responsiveness in lepromatous leprosy. Kaplan, G., Weinstein, D.E., Steinman, R.M., Levis, W.R., Elvers, U., Patarroyo, M.E., Cohn, Z.A. J. Exp. Med. (1985) [Pubmed]
  11. Once-monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy. Yawalkar, S.J., McDougall, A.C., Languillon, J., Ghosh, S., Hajra, S.K., Opromolla, D.V., Tonello, C.J. Lancet (1982) [Pubmed]
  12. Sulphone resistance in leprosy. A review of one hundred proven clinical cases. Pearson, J.M., Rees, R.J., Waters, M.F. Lancet (1975) [Pubmed]
  13. Immune complexes in syphilis sera. Wozniczko-Orlowska, G., Milgrom, F. J. Immunol. (1981) [Pubmed]
  14. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Ji, B., Perani, E.G., Petinom, C., N'Deli, L., Grosset, J.H. Antimicrob. Agents Chemother. (1994) [Pubmed]
  15. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. Sampaio, E.P., Kaplan, G., Miranda, A., Nery, J.A., Miguel, C.P., Viana, S.M., Sarno, E.N. J. Infect. Dis. (1993) [Pubmed]
  16. Clinical trial of clarithromycin for lepromatous leprosy. Chan, G.P., Garcia-Ignacio, B.Y., Chavez, V.E., Livelo, J.B., Jimenez, C.L., Parrilla, M.L., Franzblau, S.G. Antimicrob. Agents Chemother. (1994) [Pubmed]
  17. The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. Kaplan, G., Kiessling, R., Teklemariam, S., Hancock, G., Sheftel, G., Job, C.K., Converse, P., Ottenhoff, T.H., Becx-Bleumink, M., Dietz, M. J. Exp. Med. (1989) [Pubmed]
  18. Cross-reactivity of antigens from the cytoplasm and cell walls of some corynebacteria and mycobacteria. Abou-Zeid, C., Harboe, M., Sundsten, B., Cocito, C. J. Infect. Dis. (1985) [Pubmed]
  19. Inhibition of apoptosis by ionomycin and zinc in peripheral blood mononuclear cells (PBMC) of leprosy patients. Gupta, A., Sharma, V.K., Vohra, H., Ganguly, N.K. Clin. Exp. Immunol. (1999) [Pubmed]
  20. Differential production of interleukin-10 and interleukin-12 in mononuclear cells from leprosy patients with a Toll-like receptor 2 mutation. Kang, T.J., Yeum, C.E., Kim, B.C., You, E.Y., Chae, G.T. Immunology (2004) [Pubmed]
  21. Missense mutations of the interleukin-12 receptor beta 1(IL12RB1) and interferon-gamma receptor 1 (IFNGR1) genes are not associated with susceptibility to lepromatous leprosy in Korea. Lee, S.B., Kim, B.C., Jin, S.H., Park, Y.G., Kim, S.K., Kang, T.J., Chae, G.T. Immunogenetics (2003) [Pubmed]
  22. Human monoclonal antibodies against Mycobacterium leprae. Atlaw, T., Kozbor, D., Roder, J.C. Infect. Immun. (1985) [Pubmed]
  23. Sera of leprosy patients with type 2 reactions recognize selective sequences in Mycobacterium leprae recombinant LSR protein. Singh, S., Narayanan, N.P., Jenner, P.J., Ramu, G., Colston, M.J., Prasad, H.K., Nath, I. Infect. Immun. (1994) [Pubmed]
  24. Lepromin-induced suppressor cells in lepromatous leprosy. Nelson, E.E., Wong, L., Uyemura, K., Rea, T.H., Modlin, R.L. Cell. Immunol. (1987) [Pubmed]
  25. Adrenocortical hormones and interleukin patterns in leprosy. Leal, A.M., Magalhães, P.K., Souza, C.S., Foss, N.T. Parasite Immunol. (2003) [Pubmed]
  26. A patient with lepromatous leprosy and anticytoskeletal antibodies. Frey, F.L., Gottlieb, A.B., Levis, W.R. J. Am. Acad. Dermatol. (1988) [Pubmed]
  27. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. Bochud, P.Y., Hawn, T.R., Aderem, A. J. Immunol. (2003) [Pubmed]
  28. A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy. Yamauchi, P.S., Bleharski, J.R., Uyemura, K., Kim, J., Sieling, P.A., Miller, A., Brightbill, H., Schlienger, K., Rea, T.H., Modlin, R.L. J. Immunol. (2000) [Pubmed]
  29. Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions. Sreenivasan, P., Misra, R.S., Wilfred, D., Nath, I. Immunology (1998) [Pubmed]
  30. Addiction of anti-CD28 antibodies restores PBMC proliferation and IFN-gamma production in lepromatous leprosy patients. Fafutis-Morris, M., Guillén-Vargas, C.M., Navarro-Fierros, S., Alfaro-Bustamante, F., Zaitzeva-Petrovna, G., Daneri-Navarro, A., Santoscoy-Tovar, L., Armendariz-Borunda, J. J. Interferon Cytokine Res. (1999) [Pubmed]
  31. Sequence and immunogenicity of the 70-kDa heat shock protein of Mycobacterium leprae. McKenzie, K.R., Adams, E., Britton, W.J., Garsia, R.J., Basten, A. J. Immunol. (1991) [Pubmed]
  32. Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Chakrabarty, A.K., Maire, M., Saha, K., Lambert, P.H. Clin. Exp. Immunol. (1983) [Pubmed]
  33. Immunologic unresponsiveness in leprosy is mediated by modulation of E-receptor. Muthukkaruppan, V., Chakkalath, H.R., James, M.M. Immunol. Lett. (1987) [Pubmed]
  34. Differences in predominant T cell phenotypes and distribution pattern in reactional lesions of tuberculoid and lepromatous leprosy. Narayanan, R.B., Laal, S., Sharma, A.K., Bhutani, L.K., Nath, I. Clin. Exp. Immunol. (1984) [Pubmed]
  35. The number of Mycobacterium leprae in the pretreatment biopsy-specimen does not determine the rate of response of patients with lepromatous leprosy to chemotherapy with acedapsone. Levy, L., Shepard, C.C. Leprosy review. (1986) [Pubmed]
 
WikiGenes - Universities